• Explore /
  • Poster
  • / Phase I study of vemurafenib and heat shock protein 90 (HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma.

Phase I study of vemurafenib and heat shock protein 90 (HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma.

Abstract Poster

Authors

null

Zeynep Eroglu

H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

Zeynep Eroglu , Geoffrey Thomas Gibney , Jeffrey S. Weber , Ragini Reiney Kudchadkar , Nikhil I. Khushalani , Joseph Markowitz , Leticia F. Tetteh , Howida Ramadan , Xiuhua Zhao , Ann Chen , Ritin Sharma , Jane Messina , John M Koomen , Vernon K. Sondak , Keiran Smalley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT01657591

Citation

J Clin Oncol 34, 2016 (suppl; abstr 9544)

DOI

10.1200/JCO.2016.34.15_suppl.9544

Abstract #

9544

Poster Bd #

149

Abstract Disclosures

Similar Posters

Poster

2016 ASCO Annual Meeting

Co-targeting BRAF with mTOR inhibition in solid tumors harboring <i>BRAF</i> mutations: A phase I study.

Co-targeting BRAF with mTOR inhibition in solid tumors harboring BRAF mutations: A phase I study.

First Author: Shiraj Sen

First Author: K. B. Kim

First Author: Gulam Abbas Manji

First Author: Lisa Zimmer